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Abstract 11 
Aims 12 
Rotavirus vaccines (RV) are safe and effective but demand significant investment of healthcare 13 
resource.  In countries with low mortality due to rotavirus, a key component to assessing cost-14 
effectiveness is quantifying the Health Related Quality of Life (HRQoL) lost due to rotavirus acute 15 
gastroenteritis (RVAGE). 16 
Methods 17 
Families with children less than six years old with gastroenteritis were recruited from attendees to 18 
Bristol Children’s Hospital Emergency Department.  Stools were tested for viral causes of 19 
gastroenteritis. Children’s HRQoL was assessed at presentation using Health Utilities Index 2 (HUI2) 20 
with visual analogue scale (VAS). The effect of the child’s illness on the HRQoL of up to two adult 21 
carers was assessed using EQ-5D-5L.  Families completed a daily symptom diary to assess time to 22 
recovery and within-family transmission. 23 
Results 24 
127 families consented to take part, 84(65%) had rotavirus as the cause of illness. 25 
At the time of attendance, mean paediatric HRQoL with RVAGE was 0.74(HUI2) and 0.42(VAS).  26 
Primary / secondary carer’s HRQoL was 0.68/0.80 (EQ5D) or 0.70/0.79 (VAS).  The mean number of 27 
QALYs lost due to RVAGE was 3.1-3.5 per thousand children and 7.7-8.7 per thousand family units. 28 
In 52% of RVAGE families at least one other member developed a secondary case of gastroenteritis.  29 
For working parents, 69% missed work, for a mean of 2.8 days (95% CI 2.3-3.4). 30 
Conclusions 31 
We have found the HRQoL loss associated with RVAGE in children and their carers to be significantly 32 
higher than estimates used for all RV medical attendances in UK cost-effectiveness calculations. 33 
Keywords: Rotavirus; Quality of life; Great Britain; Rotavirus Vaccines;  Economic Evaluation 34 
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Introduction 35 
Rotavirus is the commonest cause of gastroenteritis in childhood and  most children will have 36 
suffered from it at least once by the time they are five years old.[1] Although prevalent in all 37 
countries, the burden of rotavirus is far from equitable. In developing countries with limited access 38 
to healthcare, it is estimated to lead to the deaths of half a million children under the age of five per 39 
year.[2] In the early 1980s, vaccination was identified as the only feasible method of controlling 40 
rotavirus.[3] A worldwide concerted effort to develop a vaccine has culminated in the licensure of 41 
two safe and effective formulations in 2006.  The WHO has recommended that all countries[4] 42 
introduce RV vaccine into their childhood vaccination schedules. 43 
With the support of international agencies and discounted vaccine prices, in countries with high 44 
levels of mortality due to rotavirus, the justification for vaccination is clear.  But in those countries 45 
where mortality is rare, such as in the United Kingdom (UK), [5] a more formal approach to assessing 46 
cost-effectiveness is required.  In the UK new vaccines are assessed by the Joint Committee for 47 
Vaccination and immunisation (JCVI) using methods based upon the National Institute for health and 48 
Care Excellence (NICE) health technology assessment framework. Crucial to cost-effectiveness 49 
calculation is an assessment of how the disease affects health related quality of life (HRQoL). When 50 
expressed over time as Quality Adjusted Life Years (QALYs) this permits standardised comparisons 51 
between different healthcare interventions.  52 
Cost effectiveness is often summarised by the incremental cost effectiveness ratio (ICER) which 53 
represents the cost implications per net change in QALYs. In the UK, NICE suggests that an ICER less 54 
than £20-30,000 per QALY is likely to be cost-effective. To fully capture the benefits of an 55 
intervention, NICE recommends that all direct health benefits (not just those for the patient) should 56 
be taken into account.  Reviews have found that this is still a relatively uncommon practice, most 57 
often applied in health economic assessments of chronic diseases with informal but long term caring 58 
commitments such as dementia. [6–8] 59 
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Although there have been many assessments of the clinical burden[9–11] and secondary economic 60 
costs to families,[12,13] the effects of rotavirus on HRQoL have not been robustly assessed.  The  61 
analyses of rotavirus vaccine cost effectiveness in the UK [14] as well as in other countries[15,16] are 62 
based on data from a single cohort of attendances to Canadian primary care.[17] All found the QALY 63 
loss of parents and children to be a major determining factor of vaccine cost effectiveness.  As the 64 
severity of cases seen in primary care may not be representative of the whole spectrum of rotavirus 65 
disease, we sought to determine the effects of more severe rotavirus infection on the HRQoL of a 66 
cohort of children and their parents in the UK to help provide additional data to parameterise any 67 
future cost effectiveness analyses. 68 
Methods 69 
Children presenting with symptoms of gastroenteritis (>2 loose stools and/or >1 episode of forceful 70 
vomiting in the last 24 hours) under six years of age were recruited from the paediatric emergency 71 
department of Bristol Royal Hospital for Children.  After obtaining informed consent, a short 72 
questionnaire assessed childrens’ and their carers’ quality of life at the point of presentation to 73 
hospital and asked for how long symptoms had been present.  The impact of the child’s illness on 74 
the quality of life of the primary, and when present, secondary carer was assessed using the EQ5D-75 
5L[18] using UK 3L-5L crosswalk valuation sets for valuation[19].  Children’s HRQoL was assessed 76 
using the Health Utilities Index 2 (HUI2)[20] questionnaire with the addition of the EQ5D visual 77 
analogue scale (VAS) which is anchored at 0 - “best health you can imagine” to 100-  “worst health 78 
you can imagine”. Clinical severity was assessed using the Vesikari [21] scoring system. This scale 79 
was developed for the assessment of rotavirus vaccines and combines the length and frequency of 80 
symptoms, degree of dehydration and level of treatment required to assign a score between 0 and 81 
20. In its derivation community cohort of children with rotavirus gastroenteritis the mean score was 82 
11 (standard deviation 3.7); conventionally severe gastroenteritis is defined as a score greater than 83 
10.  A stool sample was collected and tested for viral causes of gastroenteritis using routine clinical 84 
PCR.  Families were asked to complete a daily diary card recording children’s symptoms, days of 85 
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missed work, childcare and healthcare use until they felt their child had returned to normal health 86 
(see appendix 1 for example page).  At this point there was a final assessment of the whole family’s 87 
HRQoL and the diary was returned by post. 88 
Figure 1: Graphical representation of our method of estimating QALY loss.   89 
Point A represents disease onset, point B assessment in the emergency department at nadir HRQoL.  90 
Point C, recovery HRQoL – is assumed to represent pre-morbid baseline.  Shaded area represents the 91 
QALY loss due to rotavirus gastroenteritis.  92 
As rotavirus is usually a transient self limiting illness with no long term effects, we assumed that a 93 
child’s pre-morbid HRQoL would be the same as their HRQoL once they had recovered from the 94 
acute illness.  To calculate HRQoL loss we estimated a constant linear decrease from the pre-morbid 95 
baseline at reported symptom start to a nadir at point of presentation to the emergency department 96 
and then constant improvement to return to baseline by the reported end date. (Figure 1)  97 
Any incomplete domains were scored as perfect health.  Non parametric distributions were 98 
compared using the Mann -Whitney U test.  Confidence intervals for the mean were derived from 99 
1000 bootstrap iterations. Statistical analyses were performed using R.[22] 100 
The study was approved by the South West Central Bristol NRES ethics committee (REC12/SW/0359) 101 
and funded through a University Hospitals Bristol NHS Foundation Trust Clinical PhD studentship. 102 
Results 103 
129 families consented to take part in the study, 118 (91%) completed the initial questionnaire and 104 
59 (46%) returned the diary.  Of the 84 (65%) found to be rotavirus positive, 77 completed the initial 105 
questionnaire and 48 returned the diary.  Childrens’ median age was 14 months (IQR  10-22m) and 106 
52% were male.  Children had been ill for a mean 4 (95%CI 3.5-4.6) / median 4 (IQR 2-5) days before 107 
attending the emergency department.  41 (53%) children required hospital admission.  The mean 108 
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Vesikari score on attendance was 11.2 (SD 2.5 range 5-18) with 66% categorised as severe (score 109 
greater than 10). 110 
  First assessment n=77 Final Assessment n=48 
  Mean (95% CI) Mean (95% CI) 
Child HUI2 0.735 0.69 - 0.78 0.96 0.94- 0.98 
VAS 0.418 0.37 - 0.46 0.83 0.79- 0.88 
Primary 
carer 
EQ5D 0.68 0.61 - 0.74 0.86  0.81 - 0.92 
VAS 0.70 0.65- 0.75 0.84 0.80 - 0.89 
Secondary 
carer 
EQ5D 0.80 0.74 - 0.85 0.93  0.90 - 0.96 
VAS 0.79 0.73- 0.85 0.88 0.84 - 0.93 
Table 1 of HRQol of child & related adults  111 
Table 1 shows the mean HRQoL of children and carers at presentation and at final assessment in 112 
those who returned diaries.  At time of presentation to the emergency department, the main 113 
domains reported to be affected in children were emotion and pain, with 81% and 64% reporting 114 
reduced scores, respectively.  In adults the main domains were usual activities and anxiety (with 64% 115 
and 62% of cases reporting reduced scores, respectively). There were no significant differences in 116 
reported initial HRQoL (p=0.72), disease severity (p=0.92), rate of admission (p=0.23) or length of 117 
illness prior to attendance (p=0.5) between those who did and did not return the diaries. Children 118 
whose parents returned the diaries tended to be slightly older (median 15.8 vs 11.1 months (p=0.06) 119 
than those who did not, but were not significantly different (p=0.2) from the total age distribution of 120 
gastroenteritis attendances to the Emergency Department. Families reported their children to 121 
remain ill for a mean 5.7 (95%CI 5.1- 6.5) / median of 5.5 (IQR 4-7) additional days following initial 122 
interview. 123 
Parents were asked to self allocate as the primary (n=48) or secondary (n=41) carer. In all but one 124 
case (where there was a single father), the mother was recorded as primary carer. There were five 125 
single mothers families leaving 40 fathers and one grandmother recorded as secondary carers. 126 
Within the completed diary cohort,   at least one other member developed a secondary case of 127 
gastroenteritis in 52% of households.  For working carers, 69% missed a mean 2.8 (95% CI 2.3-3.4), 128 
median 2.3 (IQR 1.4 -3.8) days of work. 129 
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For our primary analysis, in those who returned their diaries, we calculated QALY loss using the last 130 
reported HRQoL as baseline, i.e. we assumed that by the end of the study individuals had returned 131 
to normal health. For children this equated to a mean loss of 3.1 QALYs per thousand episodes, with 132 
mean loss for primary and secondary carers 2.7 and 2.1 QALYS per 1000 episodes respectively. 133 
However 43% of families still reported their child to be unwell in free-text or using the VAS in their 134 
last diary entry.  Concurrently 44% of carers still reported their HRQoL below standard healthy 135 
norms[23] and in free text ten (20%) parents noted that they were suffering from gastroenteritis 136 
themselves.  To account for this, we carried out a sensitivity analysis (table 2) using the nadir HRQoL 137 
reported by all respondents (not just those returning the diaries) and compared it to baseline of 138 
perfect health in children and healthy adult UK EQ5D population standard values[23] for age and 139 
gender. This resulted in a higher estimated QALY loss for children and the primary carer, although 140 
confidence intervals overlapped with our primary estimates.  141 
 142 
Table 2: Sensitivity analysis comparing our primary analysis to an alternative method of calculating 143 
the mean QALY loss / 1000 cases of rotavirus. 144 
  145 
Analysis Population HRQoL comparisions 
Mean QALY loss per thousand 
cases (95% CI) 
Child Primary 
carer 
Secondary 
carer 
P
ri
m
ar
y Diary returners 
(n=48) 
Difference in individual’s first 
reported HRQoL to the final 
using triangular function (fig 1a) 
3.1  
(2.2-
4.1) 
2.7 
(1.2-4.1) 
2.1 
(1.3-3.0) 
Se
n
si
ti
vi
ty
 
All respondents (n=77) 
Difference in individual’s first 
reported HRQoL compared to 
perfect health in children and 
population norm for adults 
 
3.5 
(2.9-
4.1) 
3.4 
(2.5-4.3) 
1.8 
(1.0-2.7) 
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 146 
Comparing patients who could be discharged from the Emergency department to those that 147 
required admission( table 3) we found  that families with children requiring admission all reported a  148 
trend towards a greater total QALY loss than those who could be discharged, 8.2 vs 4.6 (p=0.18) or 9 149 
vs 5.8 QALYS (p=0.08).  150 
 151 
Table 3: Sub-analysis comparing the mean QALY loss / 1000 cases of rotavirus between those who 152 
could be discharged from the emergency department and those who required admission. 153 
  154 
Population HRQoL comparisions 
Mean QALY loss per thousand cases (95% CI) 
Child 
Primary 
carer 
Secondary 
carer 
Family total 
Primary 
analysis 
Diary returners 
(n=48) 
Difference in individual’s 
first reported HRQoL to 
the final using triangular 
function (fig 1a) 
Admitted 
(n=24) 
3.4  (1.5-5.3 4.0  (1.6-6.4) 2.8 (1.7-3.9) 8.2 (4.7-11.7) 
Discharged 
(n=24) 
2.9  (2.3-3.4) 1.4 (0.3-2.3) 1.5 (0.2-2.7) 4.6 (2.9-6.3) 
p= 0.91 0.60 0.05 0.18 
Sensitivity 
analysis 
All 
respondents  
(n=77) 
Difference in individual’s 
first reported HRQoL 
compared to perfect 
health in children and 
population norm for 
adults 
 
Admitted 
(n=36) 
3.9  (2.9-4.8) 4.3 (2.8-5.6) 2.4  (1.0-3.7) 9.0  (6.7-11.3) 
Discharged 
(n=41) 
3.0  (2.4-3.7) 2.3 (1.4-3.3) 1.3  (0.3-2.3) 5.8  (4.3-7.3) 
p= 0.33 0.71 0.13 0.08 
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Discussion 155 
This is the first attempt to measure the number of Quality Adjusted Life Years lost due to acute 156 
severe rotavirus gastroenteritis in the UK.  We have found the QALY loss of children with acute 157 
rotavirus attending the paediatric emergency department to be 3.1-3.5 per 1000 cases.  The QALY 158 
loss per thousand primary / secondary carers was 2.7-3.4 and 1.8-2.1 respectively. 159 
There are just three published studies using a parentally reported preference based method to 160 
assess HRQoL during rotavirus infection and only one calculates total QALY loss.  A Canadian study of 161 
rotavirus burden[24] examined 395 children under the age of three years presenting for outpatient 162 
paediatric care.  A separately reported HRQoL arm[17] used the HUI2 to assess children and EQ5D 163 
for parents at presentation, day 7 and day 14.  This found nadir HRQoL of 0.896 (0.874; 0.917) for 164 
children and 0.875(0.844; 0.907) for parents.  Comparing to a baseline reported HRQoL at day 14 165 
they estimated a QALY loss of 2.2 (95% CI: 1.7; 2.7) and 1.8 (95% CI: 1.0; 2.7) per thousand affected 166 
children and parents respectively.  This figure was used for all cases seeking medical attention in the 167 
cost-effectiveness model[14] instrumental in the UK’s 2012 decision to introduction of RV vaccine.  168 
Two further studies report the HRQoL at presentation with rotavirus gastroenteritis.  Both used the 169 
EQ5D for both parent and child (despite there being no validated value sets for children).  The first 170 
study from Thailand [25] examined hospitalised children and rated the mean child’s utility as 0.604 171 
(95%CI: 0.592, 0.615) and parents of 0.618 (95%CI: 0.606, 0.629). The second study from 172 
Denmark[26] of all gastroenteritis attendances found median HRQoL of 0.7123 for children, and 173 
0.818 for parents with a median length of illness of 7 days.  This was lower in those who required 174 
hospitalisation for both the child (0.531) and their parent (0.743) although no significance testing or 175 
confidence intervals were reported. 176 
Between countries, different attitudes to health seeking behaviour and accessibility to health 177 
services will dictate the severity of cases seen in a particular healthcare setting.  In the UK, with the 178 
re-organisation of primary care provision, increasing numbers of families now present directly  to 179 
10 
 
the Emergency Department for minor medical illnesses.[27]  Thus paediatric emergency 180 
departments have a very varied case mix, providing both primary care to self-referrals as well as 181 
secondary assessments of more severe cases.  Within our cohort only 12% had been referred to 182 
hospital by their GP, yet 60% reported that they had already consulted their GP at least once during 183 
the episode.  Despite 53% requiring admission, our cohort’s mean HRQoL was significantly higher 184 
than Thai inpatients (p<0.001), and most similar to those reported from Danish primary care.  Both 185 
our HRQoL (p<0.001) and sensitivity QALY loss (p<0.001) estimates are significantly greater than 186 
those measured by Brisson et al[17]. Although underpowered, our subgroup analysis suggests that 187 
even patients that could be discharged from the emergency department have a greater QALY loss 188 
than in Canadian primary care; with those requiring admission reporting a trend towards greater 189 
effects.   190 
The main limitation of our study is that in an effort to reduce the burden on families already looking 191 
after sick children, rather than require daily diary entry for a fixed period, we allowed carers to 192 
report when they considered their child to be recovered and return the diary at that point.  It was 193 
hoped that this would improve our diary response rate.  However despite clear instructions and 194 
reminders, many families returned the diaries as soon as diarrhoea had ceased, while commenting 195 
that their child had not yet returned to normal in the free text and VAS score.  As such our data may 196 
both underestimate the length of illness and give a falsely low end baseline HRQoL; to address this 197 
we used alternative baselines in a sensitivity analysis, which resulted in slightly higher estimated 198 
QALY losses.  Our measure of carer HRQoL is likely to have captured both the worry/stress of caring 199 
for their child and also any effects of them becoming ill themselves during the time window during 200 
which their child was ill.  Adult measurements were taken at the (assumed) peak and resolution of 201 
child’s illness – which will not necessarily correspond to the time course of a carer’s disease.  Thus 202 
carers’ QALY loss may well be an underestimate in those who became ill as any acute deterioration is 203 
unlikely to have been detected by our method.  The differences seen between carers are interesting. 204 
By definition the primary carer will have spent more time caring for the ill child, so it is perhaps not 205 
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surprising that they felt their quality of life was more affected than the other parent, however the 206 
proportion of reported secondary illness was not significantly different 32%/34% (p=1.0) between 207 
carers.  208 
In contrast to adults,  estimating the HRQoL of pre-school children is problematic[28] as there is 209 
simply no validated instrument  for this specific age group.  We chose to use parentally reported 210 
HUI2 as although designed for children over the age of five, it has previously been recommended by 211 
NICE[29], UK specific values have been developed[30] and it was the method used in the most 212 
widely cited assessment in the literature.[17] This allows direct comparison of our data with those 213 
results, and may explain some of the difference in comparison with studies using the adult EQ5D 214 
instrument for children. 215 
In comparison to other vaccine preventable diseases (table 4) our findings suggest that on average, 216 
an individual episode of rotavirus has only a relatively small HRQoL impact.  However the ubiquitous 217 
nature of this disease means that this represents a significant population burden especially when the 218 
effects on carers are included.   219 
With an increasing number of vaccines being developed but finite healthcare resources, the decision 220 
of which ones to introduce can become problematic.  For well informed recommendations using our 221 
current cost per QALY approach; it is essential that there are accurate data characterising the burden 222 
of common childhood illness being collected.  223 
Disease Child’s QALY loss/1000 cases Incidence in children by age 5 
Rotavirus 3.1-3.5 98%[1] 
Pneumonia[31] 4  
Chickenpox[32] 4 45%[32] 
Influenza[33] 8 67%[34] 
Measles[35] 19 <1% with vaccine 
Pertussis[36] 97 <1% with vaccine 
Meningococcal disease  
(cases without 
sequelae)[37] 
200 0.05%[38] 
Table 4 – QALY loss for childhood vaccine preventable diseases. 224 
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 225 
Conclusions 226 
Our results suggest that RV gastroenteritis has a significantly higher impact on the quality of life of 227 
children and their carers in the UK than previously reported in studies done elsewhere. The results 228 
of the first year of vaccination in the UK appear to show a large reduction in rates of disease[39].  229 
Our findings imply the programme will have been more cost effective than previously estimated, 230 
since the QALY losses we show in children presenting to the Emergency Department and their 231 
families are higher than the estimates used in the cost effectiveness studies which drove the 232 
recommendation to introduce the vaccine. These figures may be of value to other European 233 
countries still evaluating the cost-effectiveness of introducing rotavirus vaccination. 234 
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